Preview

Rational Pharmacotherapy in Cardiology

Advanced search

CLINICAL AND FUNCTIONAL CHARACTERISTICS OF PATIENTS AFTER Q-WAVE MYOCARDIAL INFARCTION DEPENDING ON THE METABOLIC SYNDROME PRESENCE OR ABSENCE

https://doi.org/10.20996/1819-6446-2013-9-5-488-493

Full Text:

Abstract

Aim. To study the clinical and functional parameters of patients after acute Q-wave myocardial infarction (Q-MI) depending on the concomitant metabolic syndrome (MS). Material and methods. Men after Q-MI (n=79; aged 51.7±8.9 years) were included into the study. Patients were divided into two groups depending on the MS presence or absence. Doppler echocardiography and determination of the serum C-reactive protein (CRP) level were performed in all patients on the 10-14 days after Q-MI, and treadmill test was performed in 25 patients.
Results. Left ventricular ejection fraction was 12% lower and the CRP level was 2 times higher in MS patients versus these in non-MS patients (p<0.01). The silent segment ST depression ≥1.0 mm were more often observed in MS patients compared with this in non-MS patients (40% vs 5%; respectively, p<0.05).
Conclusion. The MS presence complicates the post-infarction period by early heart failure progression, characterized by elevated CRP levels and more frequent occurrence of silent myocardial ischemia.

About the Authors

R. D. Kurbanov
Republican Specialized Center for Cardiology, Tashkent
Uzbekistan


N. U. Zakirov
Republican Specialized Center for Cardiology, Tashkent
Uzbekistan


N. B. Sayfiddinova
Republican Specialized Center for Cardiology, Tashkent
Uzbekistan


G. U. Mullabaeva
Republican Specialized Center for Cardiology, Tashkent
Uzbekistan


G. A. Nagaeva
Republican Specialized Center for Cardiology, Tashkent
Uzbekistan


Yu. G. Kevorkova
Republican Specialized Center for Cardiology, Tashkent
Uzbekistan


References

1. Iribarren C, Go AS, Husson G, et al. Metabolic syndrome and early-onset coronary artery disease: is the whole greater than its parts?J Am Coll Cardiol 2006;48(9):1800-7.

2. Zimmet P., Shaw J., Alberti G. Preventing type 2 diabetes and thadysmetabolic syndrome in the real world: a realistic view. Diabetic medicine 2003; 20(9):693-702.

3. Vertkin AL, Zairatyants OV, Zvegintseva EA et al. Place of the metabolic syndrome in cardiovascular continuum. Attending Physician 2008; (3): 71-6. Russian (Верткин А.Л., Зайратьянц О.В., Звегинцева Е.А. и др. Место метаболического синдрома в сердечно-сосудистом континууме. Лечащий Врач 2008; (3): 71-6).

4. Mertens I, Van Gaal LF. New International Diabetes Federation (IDF) and National Cholesterol Education Program Adult Treatment panel III (NCEP-ATPIII) criteria and the involvement of hemostasis and fibrinolysis in the metabolic syndrome. J Thromb Haemost 2006;4(5):1164-6.

5. Mamedov MN. The metabolic syndrome: practical aspects of diagnosis and treatment in an outpatient setting. Manual for physicians. Moscow: SRC PM; 2005. Russian (Мамедов М.Н. Метаболический синдром: практические аспекты диагностики и лечения в амбулаторных условиях. Пособие для врачей. Москва: ГНИЦ ПМ; 2005).

6. Doehner W, Rauchhaus M, Ponikowski P, et al. Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure J Am Coll Cardiol 2005;46:1019-26.

7. Morshedi-Meibodi A, Evans JC, Levy D, et al. Clinical correlates and prognostic significance of exerciseinduced ventricular premature beats in the community: The Framingham Heart Study. Circulation 2004; 109: 2417–2422.

8. Aronson D, Rayfield EJ. How hyperglycemia promotes atherosclerosis: molecular mechanisms. Cardiovasc Diabetology 2002; 1: 1-10.

9. Adamyan, KG, Hayrapetyan, GG, Ter-Grigoryan, VR, Badolyan, NG Silent myocardial ischemia in the early post-infarction period: clinical and prognostic significance. Cardiology 1996; (11): 22-5. Russian (Адамян, К.Г., Айрапетян, Г.Г., Тер-Григорян, В.Р., Бадолян, Н.Г. Безболевая ишемия миокарда в раннем постинфарктном периоде: клиническое и прогностическое значение. Кардиология 1996; (11): 22-5).

10. Tzivoni D., Weiser G., Gavish A. Comparison of mortality and myocardial infarction rates in stable angina pectoris with and without ischemic episodes during daily activities. Am J Cardiol 1989; 63: 273-276.

11. Belyakov NA, Chubrieva Yu, Velykanova LI. Myocardial ischemic changes in the metabolic syndrome according to Holter electrocardiogram monitoring. Arrhythmologists Bulletin 2000; 16: 28-31. Russian (Беляков Н.А., Чубриева С.Ю., Великанова Л.И. Ишемические изменения миокарда при метаболическом синдроме по данным Холтеровского мониторирования электрокардиограммы. Вестник Аритмологии 2000; 16: 28-31).

12. Kurbanov RD, Asriyants LS Early tests with physical activity in patients with myocardial infarction. Manuals for doctors. Tashkent: RSCC; 2007. Russian (Курбанов Р.Д., Асриянц Л.С. Ранние тесты с физической нагрузкой у больных, перенесших инфаркт миокарда. Методическое пособие для врачей. Ташкент: РСЦК; 2007).

13. Ridker PM. Clinical application of C–reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363-9.

14. Sumarokov A.B. Risk stratification of patients with coronary heart disease. Russian Journal of Medicine 1998; 6 (14): 896-907. Russian (Сумароков А.Б. Риск-стратификация больных ишемической болезнью сердца. Русский Медицинский Журнал 1998; 6(14): 896-907).

15. Applegate RJ, Dell’Italia LA, CrawfordMN, Usefulness of two-dimensional echocardiography during low-level exercise testing early after uncomplicated acute myocardial infarction. Amer J Cardiol 1987;60(1):10-4.

16. Krivokapich J, Czernin J, Porenta G, Brunken R, Chen K, Bennett R et al. Regional Blood Flow, Oxidative Metabolism, and Glucose Utilization in Patients With Recent Myocardial Infarction. Circulation1993; 88:884-95.

17. Josephson RA, Chahine RA, Morganroth J, et al. Prediction of cardiac death in patients with a very low ejection fraction after myocardial infarction: a Cardiac Arrhythmia Suppression Trial (CAST) study. Am Heart J 1995;130(4):685-91.

18. Zharov, EI, Kazankov JN, Lagutkin DI. Silent myocardial ischemia in patients with diabetes mellitus and coronary artery disease. Cardiology 1993; (8) :73-77. Rusian (Жаров Е.И., Казанков Ю.Н., Лагуткин Д.И. Безболевая ишемия миокарда у больных сахарным диабетом и ИБС. Кардиология 1993;(8):73-77).

19. Kondratyev VV, Bochkareva EV, Kokurina UV. Silent myocardial ischemia. Current state prblemy and clinically significant aspects of its development. II. The formation mechanisms of myocardial ischemia. Cardiology 1997; (2) :90-95. Russian (Кондратьев В.В., Бочкарева Е.В., Кокурина У.В. Безболе- вая ишемия миокарда. Современное состояние прблемы и клинически значимые аспекты ее развития. II. Механизмы формирования безболевой ишемии миокарда. Кардиология 1997;(2):90-95).

20. Zharov, EI, Gamchenko IV, Martynov AI, et al. Effect of diltiazem on myocardial ischemia. Cardiology 1991; (10) :15-17. Russian (Жаров Е.И., Гамченко И.В., Мартынов А.И. и др. Влияние дилтиазема на безболевую ишемию миокарда. Кардиология 1991;(10):15-17).


Review

For citation:


Kurbanov R.D., Zakirov N.U., Sayfiddinova N.B., Mullabaeva G.U., Nagaeva G.A., Kevorkova Yu.G. CLINICAL AND FUNCTIONAL CHARACTERISTICS OF PATIENTS AFTER Q-WAVE MYOCARDIAL INFARCTION DEPENDING ON THE METABOLIC SYNDROME PRESENCE OR ABSENCE. Rational Pharmacotherapy in Cardiology. 2013;9(5):488-493. (In Russ.) https://doi.org/10.20996/1819-6446-2013-9-5-488-493

Views: 547


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)